This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Akynzeo, netupitant,pa...
QRD veterinary Appendix I - Adverse event (PhV) MSs reporting details
Human medicines European public assessment report (EPAR): Darzalex, daratumumab,...
Human medicines European public assessment report (EPAR): Supemtek Tetra (previo...
Electronic submission of Article 57(2) data: questions and answers
Chapter 3.II: XEVPRM detailed user guidance on the electronic submission of info...
Human medicines European public assessment report (EPAR): Relvar Ellipta, flutic...
Human medicines European public assessment report (EPAR): Kayfanda, odevixibat, ...
Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab,...
Human medicines European public assessment report (EPAR): Kaftrio, ivacaftor,tez...
Human medicines European public assessment report (EPAR): Bylvay, odevixibat, Da...
Human medicines European public assessment report (EPAR): Kaletra, lopinavir,rit...
Minutes - PDCO minutes of the 25-28 February 2025 meeting
HMPC meeting report on European Union herbal monographs, guidelines and other ac...
Overview of comments received on the draft revision of EMA’s Policy on handling ...
List of industry subject matter experts and list of planned calls for industry s...
Human medicines European public assessment report (EPAR): Esbriet, pirfenidone, ...
Minutes of the PRAC meeting 10-13 February 2025
Human medicines European public assessment report (EPAR): Hulio, adalimumab, Dat...
QRD Appendix V - Adverse-drug-reaction reporting details
Human medicines European public assessment report (EPAR): Bavencio, avelumab, Da...
Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of ...